Biopsy and blood-based molecular biomarker of inflammation in IBD
Carmen Argmann(Icahn School of Medicine at Mount Sinai), Mayte Suárez‐Fariñas(Rockefeller University), Joshua R. Friedman(Spark Therapeutics (United States)), Jean‐Frédéric Colombel(Mount Sinai Hospital), Bruce E. Sands(Icahn School of Medicine at Mount Sinai), Marla C. Dubinsky(Icahn School of Medicine at Mount Sinai), Won‐Min Song(Center for Information Technology), Prerak Desai(Janssen (United States)), Zainab Al-Taie(Icahn School of Medicine at Mount Sinai), Haritz Irizar(Icahn School of Medicine at Mount Sinai), Carrie Brodmerkel(Janssen (United States)), Alina C. Iuga(University of North Carolina at Chapel Hill), Andrew Kasarskis(Icahn School of Medicine at Mount Sinai), Ryan C. Ungaro(Feinstein Institute for Medical Research), Jacqueline Perrigoue(Johnson & Johnson (United States)), Ruiqi Huang(Icahn School of Medicine at Mount Sinai), Bojan Losic(University of Washington), Lauren Peters(Sema4 (United States)), Saurabh Mehandru(Icahn School of Medicine at Mount Sinai), Swati Venkat(Roswell Park Comprehensive Cancer Center), Patrick Branigan(Johnson & Johnson (United States)), Esi Lamousé‐Smith(Janssen (United States)), Roman Kosoy(University of California, Davis), Ashish Atreja(Icahn School of Medicine at Mount Sinai), Phillip Comella(Program for Appropriate Technology in Health), Eric E. Schadt(Program for Appropriate Technology in Health), Jan Wehkamp(Robert Bosch Hospital), Antonio Di Narzo(Cardiovascular Institute of the South), Aleksandar Stojmirović(Janssen (United States)), Gabrielle Wei(Center for Information Technology), Amy Hart(Janssen (United States)), Mark Curran(Janssen (United States)), Ruixue Hou(Icahn School of Medicine at Mount Sinai), Milind Mahajan(Icahn School of Medicine at Mount Sinai), Ke Hao(Boston University)
Cited by 122
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k